Goldman Sachs
TXMD icon

Goldman Sachs’s TherapeuticsMD TXMD Stock Holding History

Goldman Sachs’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,814
Closed -$3.55M – 5678
2018
Q3 		$3.55M Buy
10,814
+7,496
+226% +$2.3M ﹤0.01% 3229
2018
Q2 		$1.03M Buy
+3,318
New +$1.01M ﹤0.01% 4044
2017
Q4 		– Sell
-60
Closed -$16K – 6663
2017
Q3 		$16K Buy
60
+58
+2,900% +$16.8K ﹤0.01% 6460
2017
Q2 		$1K Buy
+2
New +$501 ﹤0.01% 6745
2017
Q1 		– Sell
-96
Closed -$28K – 7009
2016
Q4 		$28K Buy
+96
New +$29.7K ﹤0.01% 6552
2016
Q3 		– Sell
-6
Closed -$3K – 7192
2016
Q2 		$3K Buy
6
+2
+50% +$824 ﹤0.01% 6963
2016
Q1 		$1K Sell
4
-5,018
-100% -$1.71M ﹤0.01% 7040
2015
Q4 		$2.6M Sell
5,022
-11,544
-70% -$4.26M ﹤0.01% 3409
2015
Q3 		$4.85M Buy
+16,566
New +$5.89M ﹤0.01% 2908

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Goldman Sachs's TXMD Position: Q2 2022 in Review

Goldman Sachs sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 57,207 shares — an estimated $1.09M sold.

Goldman Sachs first reported a position in TXMD in Q2 2013 and held it in 36 quarters. The position peaked at $4.16M in Q2 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Goldman Sachs reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 57,207 TherapeuticsMD shares in Q2 2022, an estimated $1.09M.
  • Goldman Sachs first reported a position in TherapeuticsMD in Q2 2013 and held it in 36 quarters.
  • Goldman Sachs's TherapeuticsMD position peaked at $4.16M in Q2 2018.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.